Abstract: An interaction control method, an electronic apparatus and a storage medium are provided. The method is for the electronic apparatus, a processing unit, a bone sound sensor and a microphone are provided in the electronic apparatus, the method is applied to the processing unit and includes: acquiring an interaction state with a terminal apparatus; receiving a voice signal through the microphone; if a bone sound signal is received through the bone sound sensor, determining whether the voice signal is emitted by a wearer at least according to the bone sound signal; and if the voice signal is emitted by the wearer, performing interaction processing with the terminal apparatus based on the interaction state according to the voice signal.

Abstract: Disclosed are organic electroluminescent material and device. The organic electroluminescent material is a metal complex with a structure of Formula 1. These novel metal complexes can be used in electroluminescent device, and show more excellent performance, for example, they can reduce the driving voltage and full width at half maximum, obtain more saturated light emission, improve the efficiency and the lifetime of the device, and finally, it can improve the comprehensive performance of the device significantly.

Abstract: Embodiments of the present disclosure provide an image processing method, an electronic device, and a storage medium. The method includes: determining a target resolution in response to a shooting instruction; and controlling a camera to shoot a first image with the target resolution for a current environment, where the target resolution is a first resolution or a second resolution, and the first resolution is greater than the second resolution.

Abstract: According to embodiments of the disclosure, a method, an apparatus, a device, and a storage medium for content interaction are provided. The method includes: playing a target video associated with a recommended object; in response to a play progress of the target video reaching a predetermined time point, superimposing and presenting, on the target video, a plurality of images corresponding to a plurality of time points of the target video, the plurality of images being associated with the recommended object; and in response to the play progress of the target video reaching a first time point of the plurality of time points, highlighting a first image corresponding to the first time point in the plurality of images, and non-highlighting other images in the plurality of images except for the first image.

Abstract: Embodiments of the present disclosure proposes a headset-based text recognition method, apparatus, headset, storage medium and program product, and relates to the field of headset technology. The method is applied to a processing unit, and includes: when it is detected that a text recognition mode is triggered, sending a shooting instruction to a camera unit, so that the camera unit can acquire at least one image to be recognized of the recognized object according to the shooting instruction; receiving the at least one image to be recognized sent by the camera unit; inputting the at least one image to be recognized into a preset text recognition model, so that the preset text recognition model can recognize the image to be recognized, so as to obtain text content; and outputting the text content.

Abstract: Provided in the present invention are an anti-BCMA antibody, a pharmaceutical composition of same, and applications thereof. The anti-BCMA antibody of the present invention or an antigen binding fragment of same and the pharmaceutical composition thereof are applicable in treating B cell-related diseases.

Abstract: Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of a BCL-2 inhibitor; and optionally, a therapeutically effective amount of at least one other antineoplastic agent. Also disclosed are methods for treating a subject who has been diagnosed with a hematopoietic disorder using such combinations. Compounds are represented by Formula (I) as follows: wherein the variables are defined herein.

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia.

Abstract: Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows: wherein the variables are defined herein.

Abstract: A flow passage assembly includes a first flow passage member and a second flow passage member, in which, a first flow passage is formed inside the first flow passage member, the first flow passage including a first flow passage opening and a second flow passage opening; a second flow passage is formed inside the second flow passage member, the second flow passage including a third flow passage opening and a fourth flow passage opening; the second flow passage opening is configured to communicate with the fourth flow passage opening, so that the first flow passage is in communication with the second flow passage and a first flow path is formed; and under the first flow path, the third flow passage opening is configured for inflow of a first flow medium, and the first flow passage opening is configured for outflow of the first flow medium.

Abstract: The embodiments of the present disclosure provides a speech playing method, and relate to the field of computer technologies, where the method includes: obtaining first measurement data acquired by a sensor in a case where a user wears a headset; determining a behavior event of the user according to the first measurement data; inputting the behavior event into a pre-trained speech model for processing to obtain inquiry speech information; and playing the inquiry speech information.

Abstract: Embodiments of the present disclosure provide a speech reply method, and an electronic device, and relates to the field of computer technologies. The method includes: obtaining inquiry speech information in response to an earphone being in an earphone case; controlling a camera provided on the earphone to capture a first image; obtaining first reply speech information for the inquiry speech information, where the first reply speech information is information related to the first image, and the first image and the inquiry speech information are processed by a pre-trained dialogue model to obtain the first reply speech information; and playing the first reply speech information.

Abstract: A control method, a headphone and a storage medium are provided. The method, applied to a headphone, includes: monitoring a wearing state of the headphone; acquiring an operation instruction of a user for the headphone, wherein the operation instruction comprises at least one of a wake-up instruction, a photographing instruction, an inquiry instruction or an audio playing instruction; and according to the wearing state and the operation instruction, controlling the headphone to perform a corresponding target operation.

Abstract: The present invention relates to (R)—N-ethyl-5-fluoro-N-isopropyl-2-(5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt and solvates thereof. This compound may be useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compound, and use as menin/MLL protein/protein interaction inhibitor, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.

Abstract: The present disclosure provides a data processing method, apparatus, an electronic device, and a storage medium. The data processing method includes: displaying a preset component in a document editing interface; in response to a trigger operation on the preset component, displaying at least one selectable revision record; and in response to a trigger operation on at least one selected revision record, updating display content of the document editing interface.

Abstract: An instant messaging chat information processing method and an electronic device are provided. The instant messaging chat information processing method includes: receiving a chat mode switching operation for a target chat; and switching the target chat from a first chat mode to a second chat mode in response to the chat mode switching operation, where chat message management manners in different chat modes are different, and the first chat mode and the second chat mode are different chat modes.

Abstract: The present disclosure provides an information processing method and apparatus, an electronic device, and a storage medium. In some embodiments, the present disclosure provides an information processing method, including: determining at least one target message in response to a first operation event for a message in a first chat, wherein the at least one target message includes a target topic message; wherein the target topic message is a message on which a topic is created in the first chat; and forwarding the at least one target message and related reply information of the target topic message to a second chat in response to a second operation event for the at least one target message.

Abstract: The present disclosure relates to compounds for organic electronic devices such as organic light-emitting devices. In particular, the present disclosure relates to a metal complex comprising a ligand La having a structure of Formula 1A and a ligand Lb having a structure of Formula 1B. These novel metal complexes can provide better device performance, can obtain more saturated green light emission, a narrower FWHM, and higher EQE, and can prepare devices with better performance. Further disclosed are an electroluminescent device comprising the metal complex, a compound combination comprising the metal complex, and a display assembly comprising the metal complex, wherein the electroluminescent device, compound combination, or display assembly has a relatively good application prospect.

Abstract: Provided are an organic electroluminescent material and a device thereof. The organic electroluminescent material is a metal complex including a ligand La having a structure of Formula 1, and the metal complex can be used as luminescent materials in electroluminescent devices. These new compounds, when used in electroluminescent devices, can show better performance, provide lower device voltage and higher device efficiency, and significantly improve the comprehensive performance of devices. Further provided are an electroluminescent device including the metal complex and a compound composition including the metal complex.